E Kevin Hall, MD
Associate Professor of PediatricsCards
Appointments
Additional Titles
Director, Pediatric Heart Transplant Program, Pediatric Cardiology
Director, Pediatric Heart Failure and Cardiomyopathy Program, Pediatric Cardiology
Contact Info
Pediatric Cardiology
PO Box 208064
New Haven, CT 06520-8064
United States
Appointments
Additional Titles
Director, Pediatric Heart Transplant Program, Pediatric Cardiology
Director, Pediatric Heart Failure and Cardiomyopathy Program, Pediatric Cardiology
Contact Info
Pediatric Cardiology
PO Box 208064
New Haven, CT 06520-8064
United States
Appointments
Additional Titles
Director, Pediatric Heart Transplant Program, Pediatric Cardiology
Director, Pediatric Heart Failure and Cardiomyopathy Program, Pediatric Cardiology
Contact Info
Pediatric Cardiology
PO Box 208064
New Haven, CT 06520-8064
United States
About
Titles
Associate Professor of Pediatrics
Director, Pediatric Heart Transplant Program, Pediatric Cardiology; Director, Pediatric Heart Failure and Cardiomyopathy Program, Pediatric Cardiology
Biography
2006 - 2009 Fellowship, Pediatric Cardiology, Children's Hospital of Philadelphia
2009 - 2010 Senior Fellowship, Heart Failure & Transplant, Children's Hospital Boston
Appointments
Pediatric Cardiology
Associate Professor on TermPrimary
Other Departments & Organizations
- Center for Biomedical Data Science
- Children’s Heart Center
- Mobile @ Yale
- Pediatric Cardiology
- Pediatric Echocardiogram Program
- Pediatrics
- Yale Medicine
- Yale Pediatric Neuromuscular Program
- Yale Ventures
Education & Training
- Senior Fellow
- Children's Hospital, Boston (2010)
- Fellow
- Children's Hospital of Philadelphia (2009)
- Resident
- Rainbow Babies & Children's Hospital (2006)
- Intern
- Rainbow Babies & Children's Hospital (2004)
- MD
- Trinity College (2003)
- MBBCh
- Trinity College (2003)
Research
Overview
E. Kevin Hall, M.D. is Associate Professor of Pediatrics (Cardiology) and Medical Director of the Pediatric Heart Failure and Cardiomyopathy Program at the Yale University School of Medicine. Dr. Hall has had a life-long and active involvement with computers and information technology stretching back to the Texas Instruments TI-99/4A in the mid 1980s. He had an internship with Alliant Computer Systems in 1991/1992 and six systems engineering internships with Silicon Graphics in the later 1990s. He has significant experience with UNIX (both System V and BSD) and Linux dating back to 1991 and 1995 respectively. He is capable in C (C90), Objective-C, Swift, Ruby, Javascript (ES2015), and Clojure. He was publicly cited as a contributor to the Qt GUI framework prior to its acquisition by Nokia in 2008. He was appointed to and served on the Information Systems Steering Committee of the Cardiac Center at the Children’s Hospital of Philadelphia and University of Pennsylvania. He currently serves on the Yale University Provost’s ITS Advisory Committee (ITSAC)
Dr. Hall’s work has focused on cardiomyopathy in children and adolescents and the effects of these conditions on individuals’ qualities of life. He has been an early participant in mobile health and has a particular focus on using network and mobile technologies to study and better understand these conditions over broad geographies and age ranges. He is the principal investigator of a nationwide clinical study currently enrolling patients from 2 – 80 years of age with or at risk for these heart diseases. He is the programmer behind the Yale Cardiomyopathy Index, the iPhone-based application fronting this work. The Yale Cardiomyopathy Index was the second Apple research application released after the March 2015 announcement of ResearchKit and the first to enroll pediatric participants.
Because of this landmark work, in March of 2016 Dr. Hall was invited for five days to Fuwai Hospital in Beijing, the largest cardiovascular hospital in China, to present his findings and begin mobile health collaborations with their investigators. He is working closely with teams to build and release several large mobile health studies expected later this year.
Dr. Hall is a member of the Leadership and Steering Committee for the International Society of Pediatric Innovation, an organization of leaders in medicine from one hundred pediatric institutions around the world. He leads both the eMedicine and Communications Committees.
Dr. Hall is Principal Investigator on a new industry-sponsored heart failure pharmacologic treatment for children. He is additionally co-investigator on several other trials for cardiomyopathy and heart failure. In addition to his research activity Dr. Hall trained as a pediatric cardiologist and completed his Pediatric Cardiology fellowship at the Children’s Hospital of Philadelphia. He completed his Senior Fellowship in Pediatric Heart Failure and Transplantation at Children’s Hospital Boston. Since his arrival to Yale he has directed the Pediatric Heart Failure and Cardiomyopathy Program which manages patients with these conditions from three hundred families around Connecticut and bordering states.
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Erin Faherty, MD
Jeremy Steele, MD
Robert Elder, MD
Akiko Iwasaki, PhD
Anis Barmada, MPhil
Adam Schussheim, MSc, MD
Myocarditis
Heart Failure
Cardiomyopathies
Heart Defects, Congenital
Pediatrics
Publications
2024
Chapter 38 Cybersecurity and blockchain in cardiology
Hall E. Chapter 38 Cybersecurity and blockchain in cardiology. 2024, 367-370. DOI: 10.1016/b978-0-323-90534-3.00006-8.Peer-Reviewed Original Research
2023
Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy
Lampert R, Ackerman M, Marino B, Burg M, Ainsworth B, Salberg L, Tome Esteban M, Ho C, Abraham R, Balaji S, Barth C, Berul C, Bos M, Cannom D, Choudhury L, Concannon M, Cooper R, Czosek R, Dubin A, Dziura J, Eidem B, Emery M, Estes N, Etheridge S, Geske J, Gray B, Hall K, Harmon K, James C, Lal A, Law I, Li F, Link M, McKenna W, Molossi S, Olshansky B, Ommen S, Saarel E, Saberi S, Simone L, Tomaselli G, Ware J, Zipes D, Day S, Abrahms D, Ashley E, Aziz P, Batra A, Cerrone M, Colan S, Erickson C, Ferhaan A, Gollob M, Johnsrude C, Kannankeril P, Kanter R, Li W, Masri A, Murphy A, Nandi D, Perez M, Perry J, Popjes E, Rao R, Rosenthal D, Sanatani S, Semsarian C, Shah M, Skinner J, Tardif J, Towbin J, Turer A, Webster G, Wever-Pinzon O, Wong T. Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology 2023, 8: 595-605. PMID: 37195701, PMCID: PMC10193262, DOI: 10.1001/jamacardio.2023.1042.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsComposite end pointVigorous-intensity exerciseHypertrophic cardiomyopathyVigorous exerciseEnd pointCohort studyExercise categoriesVentricular arrhythmiasPhysical activityPrimary composite end pointMultivariate Cox regression analysisAdjusted hazard ratioProspective cohort studyCox regression analysisLeft ventricular hypertrophyLife-threatening arrhythmiasSudden cardiac arrestImplantable cardioverter defibrillatorHigh rateHCM centersNonvigorous activitiesObservational registryAppropriate shocksExperienced centersHazard ratioCytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis
Barmada A, Klein J, Ramaswamy A, Brodsky N, Jaycox J, Sheikha H, Jones K, Habet V, Campbell M, Sumida T, Kontorovich A, Bogunovic D, Oliveira C, Steele J, Hall E, Pena-Hernandez M, Monteiro V, Lucas C, Ring A, Omer S, Iwasaki A, Yildirim I, Lucas C. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis. Science Immunology 2023, 8: eadh3455-eadh3455. PMID: 37146127, PMCID: PMC10468758, DOI: 10.1126/sciimmunol.adh3455.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMRNA vaccinesSARS-CoV-2 mRNA vaccinesSARS-CoV-2 mRNA vaccinationC-reactive protein levelsB-type natriuretic peptidePeripheral blood mononuclear cellsCardiac tissue inflammationDeep immune profilingSerum soluble CD163Vaccine-associated myocarditisCohort of patientsBlood mononuclear cellsCytotoxic T cellsLate gadolinium enhancementHypersensitivity myocarditisElevated troponinMRNA vaccinationImaging abnormalitiesNK cellsImmune profilingKiller cellsMyeloid responseNatriuretic peptideHumoral mechanismsInflammatory cytokinesPriorities to promote participant engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network
Schuster A, Crossnohere N, Bachini M, Blair C, Carpten J, Claus E, Colditz G, Ding L, Drake B, Fields R, Janeway K, Kwan B, Lenz H, Ma Q, Mishra S, Paskett E, Rebbeck T, Ricker C, Stern M, Sussman A, Tiner J, Trent J, Verhaak R, Wagle N, Willman C, Bridges J, Network F. Priorities to promote participant engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Cancer Epidemiology Biomarkers & Prevention 2023, 32: 487-495. PMID: 36791345, PMCID: PMC10068438, DOI: 10.1158/1055-9965.epi-22-0356.Peer-Reviewed Original ResearchCitationsAltmetric
2022
Short-Term Outcomes After Myopericarditis Related to COVID-19 Vaccination
Pareek M, Steele J, Asnes J, Baldassarre L, Casale L, Desai N, Elder R, Faherty E, Ferguson I, Fishman R, Ghazizadeh Z, Glick L, Hall E, Khera R, Kokkinidis D, Kwan J, O'Marr J, Schussheim A, Tuohy E, Wang Y, Spatz E, Jacoby D, Miller E. Short-Term Outcomes After Myopericarditis Related to COVID-19 Vaccination. JACC Cardiovascular Imaging 2022, 15: 2002-2005. PMID: 36357140, PMCID: PMC9094612, DOI: 10.1016/j.jcmg.2022.03.026.Peer-Reviewed Case Reports and Technical NotesCitationsAltmetricCurrent Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION
Villa C, Auerbach SR, Bansal N, Birnbaum BF, Conway J, Esteso P, Gambetta K, Hall EK, Kaufman BD, Kirmani S, Lal AK, Martinez HR, Nandi D, O’Connor M, Parent JJ, Raucci FJ, Shih R, Shugh S, Soslow JH, Tunuguntla H, Wittlieb-Weber CA, Kinnett K, Cripe L. Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION. Pediatric Cardiology 2022, 43: 977-985. PMID: 35024902, PMCID: PMC8756173, DOI: 10.1007/s00246-021-02807-7.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsVentricular assist deviceDuchenne muscular dystrophyHeart failureTherapeutic approachesAdvanced Cardiac Therapies Improving Outcomes NetworkDMD patientsBeta-blocker therapyMuscular dystrophyImplantable cardioverter defibrillatorAldosterone antagonistsSystolic dysfunctionCardiology providersHolter monitoringPrimary preventionDestination therapyPediatric cardiologistsCardiac careLeading causeOutcomes NetworkCardioverter defibrillatorCardiac diseaseClinical careMuscle therapyEnzyme inhibitorsCare practicesElectromagnetic interference complicating Impella® use during pediatric ablation
Sullivan J, Maitoza L, Brysiewicz N, Hall E, Beach C. Electromagnetic interference complicating Impella® use during pediatric ablation. Annals Of Pediatric Cardiology 2022, 15: 533-535. PMID: 37152518, PMCID: PMC10158480, DOI: 10.4103/apc.apc_3_22.Peer-Reviewed Original ResearchCitations
2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.
Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL, VANISH Investigators., Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med 2021 doi: 10.1038/s41591-021-01505-4. PMID: 34556856.Peer-Reviewed Original ResearchSymptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination
Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, Shaughnessy R, Caron R, Fuss C, Corbin KJE, Emuren L, Faherty E, Hall EK, Di Pentima C, Oster ME, Paintsil E, Siddiqui S, Timchak DM, Guzman-Cottrill JA. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics 2021, 148: e2021052478. PMID: 34088762, DOI: 10.1542/peds.2021-052478.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPfizer-BioNTech COVID-19 vaccinationCOVID-19 vaccinationAcute myocarditisClinical courseLate gadolinium enhancement (LGE) characteristicsPolymerase chain reaction test resultsTranscription polymerase chain reaction (RT-PCR) test resultsVaccine Adverse Event Reporting SystemCoronavirus disease 2019 (COVID-19) vaccinationAcute COVID-19Multisystem inflammatory syndromeAdverse Event Reporting SystemImportant adverse eventsTime of presentationNonsteroidal antiinflammatory drugsHealthy male adolescentsGadolinium enhancement characteristicsEvent Reporting SystemReaction test resultsChest painElevated troponinInflammatory syndromeIntravenous immunoglobulinAdverse eventsSecond dose
2020
Hair and skin predict cardiomyopathies: Carvajal and erythrokeratodermia cardiomyopathy syndromes
Sun Q, Lee L, Hall EK, Choate KA, Elder RW. Hair and skin predict cardiomyopathies: Carvajal and erythrokeratodermia cardiomyopathy syndromes. Pediatric Dermatology 2020, 38: 31-38. PMID: 33275305, DOI: 10.1111/pde.14478.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCongestive heart failureCardiac evaluationHeart failureHeart diseaseSudden deathNail abnormalitiesCardiac pathologyNovel therapeuticsCardiomyopathy syndromeFatal consequencesYoung childrenPatientsWarning signsSyndromeFamily membersCardiocutaneous disorderSkinCharacteristic hairCardiomyopathyAbnormalitiesDiseasePathology
Academic Achievements and Community Involvement
activity Pediatric Technology Center at the Georgia Institute of Technology and Children's Healthcare of Atlanta
Peer Review Groups and Grant Study SectionsGrant ReviewerDetails2017 - Presentactivity International Society for Pediatric Innovation
Meeting Planning and ParticipationBoard of DirectorsDetails2016 - Presentactivity ACTION Learning Network
Professional OrganizationsLeadership CommitteeDetailsMember of the Leadership Committee. ACTION is a broad consortium of 46 national and international children's hospitals who have gathered to regularly discuss, share, and build broad consensus-based treatment practices and protocols for pediatric mechanical cardiac support.2021 - Presentactivity Project Viva Advisory Board
Advisory BoardsMemberDetailsProject VivaProject Viva is a pre-birth cohort of 2,128 mother-child pairs based near Boston, MA and is part of the NIH ECHO program. It has collected information on numerous environmental exposures and health outcomes on the mother and child beginning in early pregnancy in 1999-2002, and the "children" are now young adults. The cohort is in the process of planning the next study visit, which will focus on the collection of data from the young adult participants who will be around 21 years old. My work with this group focuses on smartphone applications and wearables.2021 - Presentactivity Independent Advisory Board
Advisory BoardsMemberDetailsUmana Medical Technologies, Republic of Malta2017 - Present
Clinical Care
Overview
E. Kevin Hall, MBBCh (a medical degree awarded in several countries outside of the U.S.), director of the Yale Medicine Pediatric Heart Failure Program, treats children and young adults with heart failure and/or cardiomyopathies. These are heart muscle conditions that ultimately lead to various types and degrees of heart dysfunction.
Dr. Hall directs a multidisciplinary group of caregivers who strive to improve the symptoms, outcomes, and qualities of life for children when their hearts are unable to beat on their own. The team employs such supportive measures as medicines, mechanical devices, or, when necessary, heart transplantation.
Dr. Hall notes that there have been remarkable advancements in recent years with all forms of treatment. “These advancements lead to improved quality of life and better long-term outcomes for children with these conditions,” he says.
Each child is different, says Dr. Hall, stressing that it is important for doctors to develop highly tailored individual treatment plans as well as a close rapport with children in order to develop trust and maximize the chances of optimal outcomes.
Clinical Specialties
Fact Sheets
Pediatric Congenital Heart Surgery
Learn More on Yale MedicinePatent Ductus Arteriosus (PDA)
Learn More on Yale MedicineHeart Murmur
Learn More on Yale MedicineVentricular Septal Defect (VSD)
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- May 05, 2023Source: Stat News
What explains rare heart condition among young men after Covid vaccines? A new study offers clues
- December 22, 2022Source: Waterbury Republican-American
Christmas miracle: Waterbury boy gets a heart transplant
- June 13, 2021Source: CNN
Pediatric cardiologists explain myocarditis and why your teen should still get a Covid-19 vaccine
- December 20, 2020Source: Hartford Courant
Connecticut’s first successful pediatric heart transplant recipient celebrates gift of life
Get In Touch
Contacts
Pediatric Cardiology
PO Box 208064
New Haven, CT 06520-8064
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.